Related Experiment Video
Updated: May 19, 2026
07:48
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
Published on: June 8, 2019
Therapeutic angiogenesis for treating cardiovascular diseases
Lorenzo Deveza1, Jeffrey Choi, Fan Yang
11. School of Medicine, Stanford University, Stanford, CA, 94305, USA;
Theranostics
|August 24, 2012
Summary
Therapeutic angiogenesis uses biomaterials and signals to promote new blood vessel growth, crucial for treating cardiovascular diseases. This approach offers controlled release for enhanced treatment efficacy.
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Cardiovascular Research
Background:
- Cardiovascular disease (CVD) is a major global health issue, often caused by blocked blood vessels.
- Restoring blood supply is essential for treating CVD.
- Therapeutic angiogenesis, stimulating new blood vessel growth, is a key treatment strategy.
Purpose of the Study:
- To review strategies for therapeutic angiogenesis.
- To explore the use of biological signals, cells, and polymeric biomaterials.
- To discuss advancements in controlled release and cell-based therapies.
Main Methods:
- Review of existing literature on therapeutic angiogenesis strategies.
- Analysis of single and combination approaches using biological signals, cells, and biomaterials.
- Discussion of advancements in polymeric biomaterials for controlled drug delivery.
- Exploration of biomimetic signals and genetically engineered stem cells.
Main Results:
- Polymeric biomaterials offer controlled, three-dimensional drug release depots.
- Biomimetic signals enable responsive or cell-triggered release for targeted angiogenesis.
- Genetically engineered stem cells and cell homing mechanisms show promise.
Conclusions:
- Polymeric biomaterials enhance therapeutic angiogenesis through controlled release.
- Advanced strategies involve biomimetic signals and engineered cells for targeted treatments.
- Future directions focus on optimizing cell-based and biomaterial-based angiogenic therapies.
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...